# EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Study · id `cardio:ct-nct06249945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06249945](<https://clinicaltrials.gov/study/NCT06249945>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06249945

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Heart failure; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06249945. Randomized; single masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06249945, source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)
- Started: 2024-03-05 (actual) (ClinicalTrials.gov record NCT06249945, source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06249945, source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT06249945, source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT06249945, source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06249945-2024-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
- Acronym: EMPA-PRED
- Condition: Heart Failure With Preserved Ejection Fraction
- Condition: End Stage Renal Disease on Dialysis
- Intervention (Drug): Empagliflozin 25 MG
- Intervention (Drug): Placebo
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER
- Collaborator: Shin Kong Wu Ho-Su Memorial Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)
- Registry lists this organization as a collaborator: Shin Kong Wu Ho-Su Memorial Hospital (`cardio:org-shin-kong-wu-ho-su-memorial-hospital`)

## Provenance

Content hash: 43251a6a06a54e99e336fc528fe6fea7be0087ee2210df468c654b53e83d551f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
